Patents by Inventor Hans J. Johansson
Hans J. Johansson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10751645Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.Type: GrantFiled: January 29, 2018Date of Patent: August 25, 2020Assignee: GE Healthcare BioProcess R&D ABInventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J Johansson, Jean-Luc Maloisel
-
Publication number: 20180154281Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.Type: ApplicationFiled: January 29, 2018Publication date: June 7, 2018Applicant: GE Healthcare BioProcess R&D ABInventors: CARINA ENGSTRAND, ANNIKA FORSS, GUNNAR GLAD, BO-LENNART JOHANSSON, HANS J JOHANSSON, JEAN-LUC MALOISEL
-
Patent number: 9878266Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.Type: GrantFiled: November 17, 2014Date of Patent: January 30, 2018Assignee: GE Healthcare BioProcess R&D ABInventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J Johansson, Jean-Luc Maloisel
-
Publication number: 20170247407Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.Type: ApplicationFiled: May 16, 2017Publication date: August 31, 2017Applicant: GE Healthcare BioProcess R&D ABInventors: Hans J. Johansson, Ronnie Palmgren
-
Patent number: 9657055Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.Type: GrantFiled: November 28, 2012Date of Patent: May 23, 2017Assignee: GE Healthcare BioProcess R&D ABInventors: Hans J. Johansson, Ronnie Palmgren
-
Patent number: 9296791Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.Type: GrantFiled: January 14, 2013Date of Patent: March 29, 2016Assignee: GE Healthcare Bio-Sciences ABInventors: Sophia Hober, Hans J. Johansson
-
Patent number: 9266041Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.Type: GrantFiled: June 13, 2011Date of Patent: February 23, 2016Assignee: GE Healthcare Bio-Sciences ABInventors: Bo-Lennart Johansson, Jean-Luc Maloisel, Hans J. Johansson, Asa Ek, Maria Holm, Jafar Saidzadeh
-
Publication number: 20150328563Abstract: The invention discloses a process for chromatographic separation of at least one target biomolecule from at least one contaminant, comprising the steps of: a) providing an axial chromatography column comprising a consolidated bed of separation matrix particles, where the consolidated bed is confined between a bottom support net and a movable top adaptor; b) separating a target biomolecule from at least one contaminant on the column; c) raising the adaptor by at least 10% of the height of the consolidated bed; d) flowing a cleaning liquid upwards through the bed under conditions sufficient to liquefy the bed, and; e) repacking the matrix particles of the liquefied bed to create a consolidated bed and lowering the adaptor such that it contacts the packed bed and optionally compresses it, and; f) separating a target biomolecule from at least one contaminant on the column.Type: ApplicationFiled: December 12, 2013Publication date: November 19, 2015Applicant: GE Healthcare Bio-Sciences ABInventors: Karol Lacki, Hans J. Johansson
-
Publication number: 20150073128Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.Type: ApplicationFiled: November 17, 2014Publication date: March 12, 2015Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: CARINA ENGSTRAND, ANNIKA FORSS, GUNNAR GLAD, BO-LENNART JOHANSSON, HANS J JOHANSSON, JEAN-LUC MALOISEL
-
Patent number: 8895710Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.Type: GrantFiled: January 4, 2011Date of Patent: November 25, 2014Assignee: GE Healthcare Bio-Sciences ABInventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J. Johansson, Jean-Luc Maloisel
-
Publication number: 20140329995Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.Type: ApplicationFiled: November 28, 2012Publication date: November 6, 2014Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Hans J. Johansson, Ronnie Palmgren
-
Patent number: 8354510Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.Type: GrantFiled: September 29, 2009Date of Patent: January 15, 2013Assignee: GE Healthcare Bio-Sciences ABInventors: Sophia Hober, Hans J. Johansson
-
Publication number: 20120149875Abstract: The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the adsorbed immunoglobulin containing proteins; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins. The method improves upon previous separation methods being that each of the ligands consists essentially of a monomer or dimer SpA or protein Z or a functional variant thereof.Type: ApplicationFiled: January 11, 2010Publication date: June 14, 2012Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Hans J. Johansson, Anders Ljunglof, Ronnie Palmgren
-
Publication number: 20110266225Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.Type: ApplicationFiled: June 13, 2011Publication date: November 3, 2011Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: BO-LENNART JOHANSSON, JEAN-LUC MALOISEL, HANS J. JOHANSSON, ASA EK, MARIA HOLM, JAFAR SAIDZADEH
-
Publication number: 20110118442Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.Type: ApplicationFiled: January 4, 2011Publication date: May 19, 2011Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: CARINA ENGSTRAND, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J. Johansson, Jean-Luc Maloisel
-
Patent number: 7867784Abstract: The present invention relates to a chromatography ligand defined by the following formula (I) R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.Type: GrantFiled: October 21, 2005Date of Patent: January 11, 2011Assignee: GE Healthcare Bio-Science ABInventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J. Johansson, Jean-Luc Maloisel
-
Patent number: 7750129Abstract: The present invention relates to a process for the purification of antibodies from one or more impurities in a liquid, which process comprises contacting said liquid with a first chromatography resin comprised of a support to which multi-modal ligands have been immobilised to adsorb the antibodies to the resin, wherein each multi-modal ligand comprises at least one cation-exchanging group and at least one aromatic or heteroaromatic ring system; adding an eluent to release the antibodies from the resin; and contacting the eluate so obtained with a second chromatography resin. In one embodiment, the ring-forming atoms of the aromatic or heteroaromatic entity are selected from the group consisting of C, S and O, and the cation exchanging group is a weak cation exchanger.Type: GrantFiled: February 25, 2005Date of Patent: July 6, 2010Assignee: GE Healthcare Bio-Sciences ABInventors: Bo-Lennart Johansson, Hans J. Johansson, Anna Grönberg, Jean-Luc Maloisel, Nicolas Thevenin
-
Patent number: 7714112Abstract: The present invention relates to a method of separating antibodies from other compound(s) in a liquid sample, wherein a mobile phase comprising said sample is contacted with a multi-modal separation matrix to adsorb undesired compounds while the antibodies remain free in the liquid, wherein the multi-modal separation matrix comprises first groups, which are capable of interacting with negatively charged sites of the target compounds, and second groups, which are capable of at least one interaction other than charge-charge interaction with said target compounds. The invention also relates to a chromatography column packed with the above-described multi-modal separation matrix and a filter having such multi-modal groups adsorbed to its surface.Type: GrantFiled: October 21, 2005Date of Patent: May 11, 2010Assignee: GE Healthcare Bio-Sciences ABInventors: Carina Engstrand, Annika Forss, Gunnar Glad, Bo-Lennart Johansson, Hans J. Johansson, Jean-Luc Maloisel
-
Patent number: 7709209Abstract: The present invention relates to the use of an alkali-stable protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.Type: GrantFiled: February 27, 2006Date of Patent: May 4, 2010Assignee: GE Healthcare Bio-Sciences ABInventors: Sophia Hober, Hans J. Johansson, Tomas Bjorkman
-
Publication number: 20100022760Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.Type: ApplicationFiled: September 29, 2009Publication date: January 28, 2010Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: SOPHIA HOBER, Hans J. Johansson